# Role of soluble ST2 in immune cell regulation and secondary neurologic injury after intracerebral hemorrhage

> **NIH NIH K23** · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $197,920

## Abstract

Project Summary/Abstract
Dr. Matthew B. Bevers is a neurologist in the divisions of Stroke, Cerebrovascular, and Critical Care Neurology
at Brigham and Women's Hospital (BWH) whose goal is to become an independent investigator with expertise
in mechanisms of secondary brain injury after intracerebral hemorrhage (ICH). His career development plan
leverages the resources of a world-class training environment by bringing together a team of mentors and
collaborators at a leading academic institution, Harvard Medical School, including both BWH and the
Massachusetts General Hospital. Dr. Bevers has already obtained preliminary results supporting a role for the
IL33/ST2 pathway in the pathophysiology of intracerebral hemorrhage and demonstrating the feasibility of his
proposed studies into its role in the development of perihematomal edema and regulation of T cell and
monocyte populations. Under the primary mentorship of Dr. W. Taylor Kimberly at MGH with a mentorship
committee including Drs. Page Pennell and Francisco Quintana at BWH and scientific advisors including Drs.
Lauren Sansing and Kevin Sheth at Yale University, Dr. Bevers proposes: 1) To identify a link between
increases in a regulator of immune cell function – soluble ST2 – and perihematomal edema and functional
outcome after ICH and 2) to identify changes in populations of immune effector cells associated with elevated
sST2 and 3) to show the effect of manipulating the ST2/IL33 system on those immune cells. The overall goal
of this project is to begin to explore a mechanistic pathway by which the initial injury from intracerebral
hemorrhage leads to initiation of cerebral edema and ultimate neurologic outcome. By bringing together novel
conceptual and technical approaches to the study of brain edema and immunology, this project will generate
new insights into mechanisms of secondary brain injury. In the long term, Dr. Bevers' career goal is to identify
unique molecular targets and develop novel therapies to improve neurologic recovery after hemorrhagic stroke.
The proposed patient-oriented research project, along with mentorship and structured career development and
scientific training, will provide Dr. Bevers with the skills and experience needed to become an independent
investigator in the field of acute neurovascular injury.

## Key facts

- **NIH application ID:** 9977484
- **Project number:** 1K23NS112474-01A1
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Matthew Bradford Bevers
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $197,920
- **Award type:** 1
- **Project period:** 2020-05-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9977484

## Citation

> US National Institutes of Health, RePORTER application 9977484, Role of soluble ST2 in immune cell regulation and secondary neurologic injury after intracerebral hemorrhage (1K23NS112474-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9977484. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*